Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) control lung cancer in patients with EGFR mutations, but resistance develops over time. Patients with high levels of genetic mutations rapidly acquire EGFR-TKI resistance. T cell immunity recognizes gene muta...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-04113-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) control lung cancer in patients with EGFR mutations, but resistance develops over time. Patients with high levels of genetic mutations rapidly acquire EGFR-TKI resistance. T cell immunity recognizes gene mutation products as neoantigens that effectively suppress mutation levels by eliminating clones with more mutations; this process is known as cancer immune editing. Therefore, EGFR-TKI-resistant clones may be less likely to form in cases with active antitumor T cell immune responses. However, the relationship between EGFR-TKI resistance and antitumor T cell response in patients with EGFR mutation remains unclear. To determine the relationship between the duration of EGFR-TKI resistance acquisition and antitumor T cell immunity, and the effect of EGFR-TKIs on T cell immunity. Methods This prospective observational study enrolled 43 patients who received osimertinib. Blood samples were collected prior to and following 4 weeks of EGFR-TKI administration. Results The median PFS and OS for the 37 patients were 24.8 and 32.9 months, respectively. Patients with higher CXCR3+CCR4−CCR6+CD4+ T cell levels exhibited significantly enhanced PFS (p = 0.002) and OS (p = 0.0006). Other T cell subsets (Th1, Th2, Th17, and CD8+) exhibited no significant correlation with PFS. The percentage of CXCR3+CCR4−CCR6+CD4+ T cells was significantly reduced with tumor volume reduction (p < 0.0001). Conclusions T cell immunity affects the time required to acquire resistance after EGFR-TKI treatment. Pretreatment CXCR3+CCR4−CCR6+CD4+ T cell cluster was significantly associated with PFS after osimertinib treatment, likely predicting osimertinib efficacy. Antitumor T cell immunity may be crucial for preventing the acquisition of EGFR-TKI resistance. |
|---|---|
| ISSN: | 1432-0851 |